Financial Incentives for Smoking Treatment II
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles and New York, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 1,058 people, planned
- Started
- 6 Jan 2020
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Smoking cessation counseling (Quitline)
- Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
- Financial incentives for smoking cessation
- Financial incentives for use of evidence-based smoking cessation therapies
- Record updated
- 29 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- age ≥ 18 years
- smoked tobacco during the prior 30 days,
- have an active U.S. phone number and address,
- can provide consent in English or Spanish and
- are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit
Who cannot take part
- use only smokeless tobacco,
- are pregnant or breastfeeding,
- are discharged to an institution (e.g., nursing home, long-term care facility),
- are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study
Where in United States
- David Geffen School of MedicineLos Angeles, United States
- NYU Langone HealthNew York, United States
About the trial
What the trial wants to find out
Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.
The 3 groups in the trial
- Goal-Directed IncentivesOther group
Treatment: Smoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), and Financial incentives for use of evidence-based smoking cessation therapies
- Outcome-Based IncentivesOther group
Treatment: Smoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), and Financial incentives for smoking cessation
- Enhanced Usual CareOther group
Treatment: Smoking cessation counseling (Quitline) and Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Financial Incentives for Smoking Treatment
- Publications
- Record updated
- 29 April 2026